Amgen | AMGN - Sales Revenues



Amgen reported $9.18B in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
AbbVie USD 15.42B 2.08B Jun/2025
Agios Pharmaceuticals USD 12.45M 3.75M Jun/2025
ALKERMES USD 390.7M 84.2M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
Biogen USD 2.6B 170M Jun/2025
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Exelixis USD 568.3M 12.9M Jun/2025
Genmab DKK 5.86B 580M Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
Glaxosmithkline GBP 7.99B 131M Jun/2025
Incyte USD 1.06B 10M Jun/2025
Ionis Pharmaceuticals USD 452M 320M Jun/2025
J&J USD 23.74B 1.85B Jun/2025
Merck USD 15.81B 280M Jun/2025
Moderna USD 142M 34M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Novartis USD 14.84B 1.28B Jun/2025
Pfizer USD 14.7B 980M Jun/2025
PTC Therapeutics USD 178.9M 11.1M Jun/2025
Regeneron Pharmaceuticals USD 3.68B 650M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sanofi EUR 9.99B 90M Jun/2025
Sarepta Therapeutics USD 611.09M 163.81M Jun/2025
Takeda JPY 1.11T 60B Jun/2025
Teva Pharmaceutical Industries USD 14.06B 0 Jun/2025
Ultragenyx Pharmaceutical USD 166.5M 27.21M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025